AnaptysBio, Inc. (NASDAQ:ANAB) Short Interest Update

AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) was the recipient of a significant decrease in short interest in January. As of January 31st, there was short interest totalling 6,030,000 shares, a decrease of 8.6% from the January 15th total of 6,600,000 shares. Based on an average daily volume of 662,000 shares, the short-interest ratio is currently 9.1 days. Currently, 23.3% of the company's shares are sold short.

AnaptysBio Price Performance

ANAB stock traded down $0.74 during trading hours on Thursday, reaching $18.87. The stock had a trading volume of 729,391 shares, compared to its average volume of 1,160,308. The stock has a market capitalization of $574.21 million and a PE ratio of -3.10. The stock has a 50-day simple moving average of $15.73 and a 200 day simple moving average of $25.41. AnaptysBio has a fifty-two week low of $12.21 and a fifty-two week high of $41.31.

Insider Buying and Selling at AnaptysBio

In related news, Director Ecor1 Capital, Llc acquired 65,184 shares of the stock in a transaction dated Monday, December 30th. The stock was bought at an average price of $12.92 per share, with a total value of $842,177.28. Following the completion of the transaction, the director now directly owns 7,860,180 shares of the company's stock, valued at approximately $101,553,525.60. The trade was a 0.84 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 33.70% of the company's stock.

Institutional Trading of AnaptysBio

Large investors have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. lifted its stake in shares of AnaptysBio by 11.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,452 shares of the biotechnology company's stock worth $85,000 after buying an additional 644 shares during the last quarter. Virtus ETF Advisers LLC lifted its stake in shares of AnaptysBio by 24.7% during the 4th quarter. Virtus ETF Advisers LLC now owns 4,733 shares of the biotechnology company's stock worth $63,000 after buying an additional 936 shares during the last quarter. Rhumbline Advisers lifted its stake in shares of AnaptysBio by 3.8% during the 4th quarter. Rhumbline Advisers now owns 30,077 shares of the biotechnology company's stock worth $398,000 after buying an additional 1,111 shares during the last quarter. nVerses Capital LLC lifted its stake in shares of AnaptysBio by 700.0% during the 3rd quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company's stock worth $54,000 after buying an additional 1,400 shares during the last quarter. Finally, Values First Advisors Inc. acquired a new stake in shares of AnaptysBio during the 3rd quarter worth about $49,000.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Wolfe Research assumed coverage on shares of AnaptysBio in a research report on Tuesday, February 4th. They set an "outperform" rating and a $25.00 price objective for the company. JPMorgan Chase & Co. lowered their price objective on shares of AnaptysBio from $66.00 to $36.00 and set an "overweight" rating for the company in a research report on Thursday, December 19th. Guggenheim lowered their price objective on shares of AnaptysBio from $90.00 to $36.00 and set a "buy" rating for the company in a research report on Thursday, December 12th. Truist Financial lowered their price objective on shares of AnaptysBio from $30.00 to $20.00 and set a "hold" rating for the company in a research report on Wednesday, December 18th. Finally, HC Wainwright restated a "neutral" rating and set a $19.00 target price on shares of AnaptysBio in a report on Tuesday, February 4th. Four analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $37.45.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.